These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 19745589)

  • 1. Adjuvant anthracyclines and taxanes: quantifying the costs of therapeutic advances in breast cancer.
    Morris PG; Bach PB
    Onkologie; 2009 Sep; 32(8-9):464-6. PubMed ID: 19745589
    [No Abstract]   [Full Text] [Related]  

  • 2. Cost analysis comparing an anthracycline/docetaxel regimen to CMF in patients with early stage breast cancer.
    Braun M; Jacobs VR; Wagenpfeil S; Sattler D; Harbeck N; Nitz U; Bernard R; Kuhn W; Ihbe-Heffinger A
    Onkologie; 2009 Sep; 32(8-9):473-81. PubMed ID: 19736510
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Pharmacoeconomic aspects of breast cancer management].
    Kolbin AS; Zagorodnikova KA
    Vopr Onkol; 2011; 57(5):604-8. PubMed ID: 22238930
    [No Abstract]   [Full Text] [Related]  

  • 4. [Relationship between Ki67 expression and tumor response to neoadjuvant chemotherapy with anthracyclines plus taxanes in breast cancer].
    Xu L; Liu YH; Ye JM; Zhao JX; Duan XN; Zhang LB; Zhang H; Wang YH
    Zhonghua Wai Ke Za Zhi; 2010 Mar; 48(6):450-3. PubMed ID: 20627009
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Taxanes in the adjuvant treatment of early breast cancer, emerging consensus and unanswered questions.
    Tang SC
    Cancer Invest; 2009 Jun; 27(5):489-95. PubMed ID: 19479486
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of actual hospital costs versus DRG revenues for in-patient treatment of febrile neutropenia during adjuvant anthracycline plus/minus taxane-based chemotherapy for primary breast cancer.
    Jacobs VR; Mayer SC; Paessens BJ; Bernard R; Harbeck N; Kiechle M; Ihbe-Heffinger A
    Onkologie; 2011; 34(11):614-8. PubMed ID: 22104158
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Algorithms for the treatment of patients with metastatic breast cancer and prior exposure to taxanes and anthracyclines.
    Comen EA; Fornier MN
    Clin Breast Cancer; 2010 Sep; 10 Suppl 2():S7-19. PubMed ID: 20805067
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Economic impact of alternative adjuvant chemotherapy regimens for stage III colon cancer.
    Goerner M; Riemer-Hommel P
    Onkologie; 2009 Nov; 32(11):647-52. PubMed ID: 19887868
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The role of taxanes in breast cancer chemotherapy: what's new 15 years after?].
    Herceg D; Vrbanec D
    Lijec Vjesn; 2009; 131(5-6):133-41. PubMed ID: 19642533
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Commentary: anthracyclines in early-stage breast cancer: is it the end of an era?
    Pritchard KI
    Oncologist; 2009 Oct; 14(10):959-62. PubMed ID: 19819915
    [No Abstract]   [Full Text] [Related]  

  • 11. Adjuvant chemotherapy.
    Tubiana-Hulin M; Gardner M
    Cancer Treat Res; 2009; 151():121-37. PubMed ID: 19593510
    [No Abstract]   [Full Text] [Related]  

  • 12. Advances in adjuvant chemotherapy for breast cancer: the role of taxanes.
    Kaklamani VG; Gradishar WJ
    J Natl Compr Canc Netw; 2003 Jan; 1 Suppl 1():S107-18. PubMed ID: 19795584
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Taxanes in neojuvant radio-, chemoradio- and chemotherapy for breast cancer].
    Bozhok AA; Semiglazov VF; Kletzel' AE; Arzumanov AS; Mel'nikova OA; Paltuev RM; Ivanova OA; Semiglazov VV
    Vopr Onkol; 2006; 52(1):7-14. PubMed ID: 16715697
    [No Abstract]   [Full Text] [Related]  

  • 14. Preoperative chemo- and endocrine therapy.
    Torrisi R
    Cancer Treat Res; 2009; 151():103-20. PubMed ID: 19593509
    [No Abstract]   [Full Text] [Related]  

  • 15. Economic issues involved in integrating genomic testing into clinical care: the case of genomic testing to guide decision-making about chemotherapy for breast cancer patients.
    Marino P; Siani C; Bertucci F; Roche H; Martin AL; Viens P; Seror V
    Breast Cancer Res Treat; 2011 Sep; 129(2):401-9. PubMed ID: 21061059
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Advances in breast cancer chemotherapy].
    Ishikawa T; Shimizu S; Momiyama N; Ichikawa Y; Shimada H
    Nihon Rinsho; 2006 Mar; 64(3):529-35. PubMed ID: 16529045
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anthracycline- and/or taxane-resistant breast cancer: results of a literature review to determine the clinical challenges and current treatment trends.
    Moreno-Aspitia A; Perez EA
    Clin Ther; 2009 Aug; 31(8):1619-40. PubMed ID: 19808124
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Taxanes in the adjuvant treatment of breast cancer.
    Trauth D; Goldstein LJ
    J Natl Compr Canc Netw; 2003 Apr; 1(2):222-31. PubMed ID: 19768881
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Breast cancer during pregnancy.
    Sánchez Martínez MC; Ruiz Simón A
    Breast Cancer Res Treat; 2010 Sep; 123 Suppl 1():55-8. PubMed ID: 20714803
    [No Abstract]   [Full Text] [Related]  

  • 20. Variation in type of adjuvant chemotherapy received among patients with stage I breast cancer: A multi-institutional Portuguese cohort study.
    R Ferreira A; Palha A; Correia L; Filipe P; Rodrigues V; Costa L; Miranda A; André R; Fernandes J; Gouveia J; Passos-Coelho JL; Moreira A; Brito M; Ribeiro J; Metzger-Filho O; U Lin N; Vaz-Luís I
    Breast; 2016 Oct; 29():68-73. PubMed ID: 27468923
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.